AzTrials
AzTrials

Maxillofacial Prosthesis ImplantationNCT03182361

Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants.

A study testing Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants in people with Maxillofacial Prosthesis Implantation and Extra-oral Implants, run by University Hospital, Ghent at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteBelgium
Study dates
20 Jun 2017to 17 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • All patients with auricular, nasal, orbital defects caused by congenital, traumatic, oncologic or infectious etiologies
  • Adults (>18yr)

Who cannot join

  • Children
  • Implant placement for bone anchored hearing aid (BAHA)
  • Implant placement for oral rehabilitation

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Hospital

    Ghent, Oost-Vlaanderen, 9000

Other trials in Belgium

About this study

Official title: Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants: An Interventional Study of 10 Patients

Patients with craniofacial defects caused by oncologic resection, traumatic events or congenital etiologies suffer from esthetic, functional and psychological problems. Auricular, nasal and orbital defects can be reconstructed with implant retained extra-oral prosthesis. The goal of this study is to evaluate implant survival in temporal, maxillary and orbital bone, and peri-implant tissue reactions using a new implant system developed by BioComp Industries.

Read the detailed description

Protocol:

  1. Planning The ideal size and location of the implants is based on pre-operative CT or CBCT scan followed by analysis using romexis planning software. In normal circumstances, without bone limitations, the number and location of the implants will be planned as mentioned below:
  • Left auricular region: 2 implants placed on position 4h and 1h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 1h30, 3h and 4h30. The inter implant distance is 20mm.
  • Right auricular region: 2 implants placed on position 8h and 10h30 in the temporal/mastoid bone. If necessary, 3 implants are placed on positions 10h30, 9h and 7h30. The inter implant distance is 20mm.
  • Nasal region: 2 implants placed in the lateral parts of the piriform aperture of the maxilla, as far away from the spina nasalis anterior as possible. If necessary a third implant will be placed in the glabella.
  • Left orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 1h, 2h, 3h en 5h.
  • Right orbital region: 2-4 implants are placed in the supra-orbital, lateral and/or infra-orbital rim on positions 11h, 10h, 9h en 7h. If for some reason there is insufficient bone in the above mentioned areas, the position of the implants will be minimally adjusted in order to secure good osseointegration. Neuronavigation will be used for cases with limited bone volume.
  1. Flap design During surgery the first step is the creation of a skin flap or resection of a tumor, exposing the area for implantation.
  2. Implantation The implantation protocol as described by BioComp Industries will be used. Each drilling procedure is executed by 1800-2000rpm with water cooling.
  • Defining the implant location with the 2,45mm diameter round bur.
  • Preparation of the implant site with the implant drills, length and diameter of the drill is dependent on the length and diameter of the implant. Drilling protocol will always start with the smallest and shortest drill and gradually expanded, corresponding to the size of the implants.
  • Placement of the implant without water cooling at 15rpm and maximal torque of 52Ncm. If necessary the implant will be inserted manually. For auricular, orbital and nasal defects with sufficient bone volume (>=3mm) and good bone quality, a percutaneous healing abutment with torque 20-25 ncm will be placed immediately after insertion of the implant (=one-stage protocol). Soft tissues in an area of 15-20mm surrounding the implant will be reduced to 1mm thickness. In all other circumstances, the implant will be protected by means of a cover screw and reburied under the skin for a 3 month osseointegration period (=two-stage protocol). After 3 months the implants are exposed, percutaneous healing abutments placed and the surrounding soft tissues reduced to 1mm thickness. In the case of large resections where no viable skin is left, a split thickness skin graft from the upper thigh will be used. Finally, a healing cap surrounding the healing abutments is placed to ensure strong bone-skin contact around the implant. This healing cap will be fixated by a fixation screw, torqued at 15 Ncm.
  1. Clinical measurements: The stability of the implants will be measured at the time of abutment placement, 1 or 2 weeks, 1 month, 3 months, 6 months and yearly until the end of the study by resonance frequency analysis (RFA), using the Osstell idx system. At the same time periods the peri-abutment tissue will be evaluated according to the Holgers criteria. Once all implants have reached a stability measurement of 50 ISQ, the patient will be sent to the anaplastologist for prosthesis treatment. In case one or more of the implants fail during the study period, the implant will be removed and replaced by a new implant. The protocol will restart for the newly placed implant.
  2. Radiological measurements:

The bone level around the implants will be measured at 1 or 2 weeks after implant placement and 1 year after implant placement. Radiological imaging will be performed using a cone beam computed tomography device (planmeca promax 3d max) or CT scan, dependent on primary imaging in order to allow comparison between both images.

Being tested
Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
Keywords
Auricular, nasal, orbital, extraoral prostheses, extraoral implants, peri-implant reactions, Holgers

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implantsDevice

    Also called EO-1110-34VD04, EO-1110-40VD03, EO-1110-40VD04

    Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone

Study groups in NCT03182361
Study groupRoleWhat they receive
Study groupExperimentalEverybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
Receives: Device: Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Implant survival

    Implant stability measurement with Osstell IDX system

    Measured: 1 year

  2. Peri-implant tissue reaction

    Measurement of peri-implant pockets and soft tissue according to Holgers criteria

    Measured: 1 year

Secondary outcomes (1)
  1. Bone level

    Bone level measurement using CBCT or CT scan

    Measured: 1-2 weeks post-operative, 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2017
  2. Study start20 Jun 2017
  3. Primary completion17 Oct 2019
  4. Study completion17 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03182361
Sponsor's protocol ID
2017/0282
Other IDs
B670201731744
Status last verified
Dec 2022
First submitted
2 May 2017
Last updated
23 Dec 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants in people with Maxillofacial Prosthesis Implantation and Extra-oral Implants, run by University Hospital, Ghent at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Implant survival (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in